Key result
The UPT-LF assay for NT-proBNP detection showed a high correlation (R = 0.995) with the established Roche Elecsys assay, demonstrating its potential as a rapid point-of-care testing method.
Why the study?
Does the UPT-LF assay provide accurate, stable, and reproducible quantitative detection of NT-proBNP comparable to the Roche Elecsys assay in patients with acute heart failure and healthy controls?
Cross-Sectional (n=397)
No
Does the UPT-LF assay provide accurate, stable, and reproducible quantitative detection of NT-proBNP comparable to the Roche Elecsys assay in patients with acute heart failure and healthy controls?
Effect estimate: R = 0.995
p-value: p=<0.05
The UPT-LF assay is a rapid, sensitive, and reliable point-of-care testing method for NT-proBNP that correlates well with standard laboratory assays, facilitating rapid diagnosis of acute heart failure.
May support rapid POC NT-proBNP testing in acute HF; leaves open prospective outcome validation before adoption.
A newly assay, up-converting phosphor technology-based lateral flow (UPT-LF) assay, was developed for rapid and quantitative detection of N-terminal fragment of B-type natriuretic peptide precursor (NT-proBNP), one of the most important serum molecular maker of heat failure, in plasma samples as a point of care testing (POCT) method for diagnosis of acute heart failure. Human plasma from 197 patients with acute heart failure and 200 healthy controls was assessed using the UPT-LF assay, in a comparison with a Roche Elecsys assay. The limit of detection of the UPT-LF assay, with a coefficient of variation (CV) of less than 15%, was 116 ng/L, which is lower than the clinical diagnosis cutoff (150 ng/mL). The linear range was 50-35,000 ng/L. The CVs were less than 10% for both UPT-LF and Roche Elecsys assays for plasma samples under different storages, demonstrating the good stability and reproducibility. There are certain linear correlations between the results of UPT-LF and Roche Elecsys assay for EDTA-K2 and heparin-anticoagulated plasma, as well as for serum samples. For UPT-LF assay, there is a significant correlation between the values derived from analysis of EDTA-K2 and heparin-anticoagulated plasma samples (R = 0.995). No statistically significant difference was found between serum and plasma samples for UPT-LF assay. Our results demonstrate that NT-proBNP levels in healthy adults are elevated with age and had a relationship with sex, and with the age increase the NT-proBNP levels of females are significantly higher than those of males (p<0.01). The UPT-LF assay has a high reproducibility, stability, sensitivity, specificity, and is consistent with Roche Elecsys assay, and therefore it could be used as a POCT method for the quantitative detection of NT-proBNP in blood for clinical diagnosis and research of acute heart failure.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2017) conducted a cross-sectional in Acute heart failure (n=397). UPT-LF assay vs. Roche Elecsys assay was evaluated on Correlation with Roche Elecsys assay (EDTA-K2 plasma) (R = 0.995, p=<0.05). The UPT-LF assay for NT-proBNP detection showed a high correlation (R = 0.995) with the established Roche Elecsys assay, demonstrating its potential as a rapid point-of-care testing method.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: